Aperture Therapeutics, a biotechnology company pioneering next-generation precision medicines for neurodegenerative diseases, today announced the nomination of APRTX-001 as its development candidate.

Backing FDA approval was the phase III PALISADE trial in which plozasiran 25 mg slashed triglyceride levels by 80% from ...

Two complementary studies led by researchers from the Yong Loo Lin School of Medicine, National University of Singapore (NUS ...

Researchers have found a new way to reactivate fetal hemoglobin without the need for gene-editing therapy, according to a new study.

Researchers in Singapore have developed a dual RNA therapy that silences mutant KRAS and activates immune signalling, ...

NUS Medicine-led study shows extracellular vesicles carrying gene-targeting antisense oligonucleotides (ASOs) and immune ...

Despite challenges like high therapy costs and regulatory hurdles, continuous R&D investments and strategic collaborations are fostering progress in personalized medicine, addressing critical unmet ...

A study has confirmed the effectiveness of a drug that can treat acquired genetic hearing loss. On the 11th, a research team led by Professor Ji Heon-young, Professor Jang Seung-hyun of Yonsei ...

THERANEXUS - THX Pharma announces the strong success of its approximately EUR 8 million capital increase to support its continued development and strengthen its financial structure ...

Scientists at St. Jude Children's Research Hospital and Northwestern University identified a previously unknown treatment ...

Investigators who designed a base-editing treatment are planning an "umbrella of umbrellas" trial, while others are developing roadmaps to guide personalized treatments.

Ionis is planning a supplemental submission by the end of the year to expand Tryngolza into severe hypertriglyceridemia. If ...